Crohn's disease-associated NOD2 Mutants

克罗恩病相关的 NOD2 突变体

基本信息

  • 批准号:
    7937012
  • 负责人:
  • 金额:
    $ 42.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-26 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

Nucleotide-binding oligomerization domain 2 (NOD2) is a monocyte-restricted member of a protein family critically involved in the activation of NF-KB in response to certain intracellular microbial infection. Dysfunctional mutations in the NOD2 gene underline the occurrence of inflammatory bower disease (IBD) in a substantial group of patients with Crohn's disease (CD). CD is characterized by an exaggerated T helper I (Thl)-type immune response. There are three most common mutations in the NOD2 gene associated with CD: an insertion of a C at nucleotide position 3020, designated 3020insC, which results in a frame shift mutation and the deletion of the terminal leucine-rich repeats (LRR) of the protein, and two amino acid substitution mutants also in the LRR region: R702W and G908R. Recent human clinical studies revealed defective IL-IO production in the mononuclear cells of CD patients homozygous for 3020insC. IL-lO is a critical immunoregulatory cytokine produced by antigen-presenting cells and activated T and B lymphocytes. The chronically impaired IL-lO production in these CD patients may contribute to persistent inflammation in the intestinal mucosa. Our own data indicate that, in contrast to the prevalent view, 3020insC is not simply a loss-of-function mutant. Instead, it can act as an inhibitor of IL-lO production. Furthermore, we have detected direct interactions between 3020insC with p38 mitogen-activated protein kinase (MAPK) and heterogeneous nuclear ribonucleoprotein Al (hnRNP AI), which we identified as a novel and constitutive transcription factor for IL-lO. 3020insC targets the DNA-binding activity of hnRNP Al by inhibiting its phosphorylation and nuclear translocation. Most importantly, we have confirmed that the phosphorylation of hnRNP Al and DNA-binding activity are indeed impaired in 3020insC-CD patients. In addition, we have identified for the first time a novel activity of the R702W and G908R mutants: they can stimulate and enhance IL-12/IL-23 gene expression. We hypothesize that the acquired property of 3020insC as an IL-lO inhibitor may result in chronically impaired IL-IO levels, whereas the R702W and G908R mutations may make individuals more prone to produce elevated levels of IL-12 and IL-23 in the myeloid compartment. In all, these three mutations cause either impairment of regulatory mechanisms or inappropriate proinflammatory cytokine production, which, combined with other contributory factors, contribute to homeostatic imbalance and persistent inflammation in the intestinal mucosa over time leading to the development and pathogenesis of CD. We propose to investigate the mechanisms whereby R702W and G908R regulate IL-12/IL-23 gene expression.
核苷酸结合寡聚化结构域2(NOD 2)是蛋白质家族的单核细胞限制性成员 关键地参与响应某些细胞内微生物感染的NF-κ B的活化。 NOD 2基因的功能失调突变强调了炎症性鲍尔病(IBD)的发生, 大量克罗恩病(CD)患者。CD的特征是T辅助细胞I的过度表达, (Thl)型免疫应答。NOD 2基因中有三种最常见的与CD相关的突变: - 在核苷酸位置3020处插入C,命名为3020 insC,其导致移码突变, 蛋白质末端富含亮氨酸重复序列(LRR)的缺失,以及两个氨基酸取代突变体 也在LRR区域:R702 W和G908 R。 最近的人类临床研究显示CD患者单核细胞中IL-10的产生缺陷 3020 insC纯合子。IL-10是由抗原呈递细胞产生的关键免疫调节细胞因子 以及活化的T和B淋巴细胞。这些CD患者中的慢性受损的IL-10产生可能 导致肠粘膜的持续炎症。我们自己的数据表明,与 普遍的观点认为,3020 insC不仅仅是一个功能丧失的突变体。相反,它可以作为IL-10的抑制剂, 生产此外,我们还检测到3020 insC与p38丝裂原激活的 蛋白激酶(MAPK)和异质性核核糖核蛋白AI(hnRNP AI),我们将其鉴定为 IL-10的新的组成型转录因子。3020 insC靶向hnRNPAl的DNA结合活性 通过抑制其磷酸化和核转位。最重要的是,我们已经证实, hnRNPA 1的磷酸化和DNA结合活性在3020 insC-CD患者中确实受损。在 此外,我们首次鉴定了R702 W和G908 R突变体的新活性:它们可以 刺激和增强IL-12/IL-23基因表达。 我们假设3020 insC作为IL-10抑制剂的获得性特性可能导致慢性炎症。 IL-10水平受损,而R702 W和G908 R突变可能使个体更容易产生IL-10, 髓腔中IL-12和IL-23水平升高。总之,这三种突变导致 调节机制受损或促炎细胞因子产生不当, 与其他因素一起,导致体内平衡失衡和持续性炎症, 随着时间的推移,肠粘膜的损伤导致CD的发展和发病。 我们拟探讨R702 W和G908 R对IL-12/IL-23基因的调控机制 表情

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

XIAOJING MA其他文献

XIAOJING MA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('XIAOJING MA', 18)}}的其他基金

UBR5's mechanisms of action in tumorigenesis and immunoregulation
UBR5在肿瘤发生和免疫调节中的作用机制
  • 批准号:
    10659844
  • 财政年份:
    2023
  • 资助金额:
    $ 42.25万
  • 项目类别:
Role of two novel genes in IL-23 production and Th17-mediated pathogenesis in SLE
两个新基因在 IL-23 产生和 Th17 介导的 SLE 发病机制中的作用
  • 批准号:
    8680657
  • 财政年份:
    2014
  • 资助金额:
    $ 42.25万
  • 项目类别:
Role of two novel genes in IL-23 production and Th17-mediated pathogenesis in SLE
两个新基因在 IL-23 产生和 Th17 介导的 SLE 发病机制中的作用
  • 批准号:
    8831592
  • 财政年份:
    2014
  • 资助金额:
    $ 42.25万
  • 项目类别:
Mechanism of Progranulin-mediated control of septic inflammation via IL-10
颗粒体蛋白前体介导的 IL-10 控制化脓性炎症的机制
  • 批准号:
    8894237
  • 财政年份:
    2014
  • 资助金额:
    $ 42.25万
  • 项目类别:
Regulation of IL-10 Gene Expression and Host Septic Response by Progranulin
颗粒体蛋白前体对 IL-10 基因表达和宿主败血症反应的调节
  • 批准号:
    8310364
  • 财政年份:
    2011
  • 资助金额:
    $ 42.25万
  • 项目类别:
Crohn's disease-associated NOD2 Mutants
克罗恩病相关的 NOD2 突变体
  • 批准号:
    8069780
  • 财政年份:
    2010
  • 资助金额:
    $ 42.25万
  • 项目类别:
Crohn's disease-associated NOD2 Mutants
克罗恩病相关的 NOD2 突变体
  • 批准号:
    7731146
  • 财政年份:
    2009
  • 资助金额:
    $ 42.25万
  • 项目类别:
Mechanism of Modulation of Interleukin-12 Production by Triptolide
雷公藤甲素调节白细胞介素 12 产生的机制
  • 批准号:
    7331754
  • 财政年份:
    2007
  • 资助金额:
    $ 42.25万
  • 项目类别:
Mechanism of Modulation of Interleukin-12 Production by Triptolide
雷公藤甲素调节白细胞介素 12 产生的机制
  • 批准号:
    7495521
  • 财政年份:
    2007
  • 资助金额:
    $ 42.25万
  • 项目类别:
Regulation of IL-12 Expression and Activity by Oncogenes
癌基因对 IL-12 表达和活性的调节
  • 批准号:
    6731357
  • 财政年份:
    2004
  • 资助金额:
    $ 42.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了